Equities analysts expect that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report $3.70 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Kalvista Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $4.30 million. Kalvista Pharmaceuticals posted sales of $1.13 million in the same quarter last year, which suggests a positive year-over-year growth rate of 227.4%. The company is expected to announce its next quarterly earnings report on Thursday, December 13th.

On average, analysts expect that Kalvista Pharmaceuticals will report full year sales of $14.89 million for the current fiscal year, with estimates ranging from $12.70 million to $16.62 million. For the next financial year, analysts expect that the company will report sales of $23.22 million, with estimates ranging from $10.00 million to $36.43 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.14). The firm had revenue of $3.72 million during the quarter, compared to analysts’ expectations of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%.

A number of research analysts have recently weighed in on the company. BidaskClub cut Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 7th. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Wednesday, September 12th. ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a research report on Tuesday, October 30th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald set a $32.00 price objective on Kalvista Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 12th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $25.25.

In other Kalvista Pharmaceuticals news, Director Albert Cha purchased 1,058,824 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average cost of $17.00 per share, with a total value of $18,000,008.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 38.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Kalvista Pharmaceuticals by 19.2% in the 3rd quarter. BlackRock Inc. now owns 19,309 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 3,104 shares in the last quarter. DRW Securities LLC lifted its holdings in Kalvista Pharmaceuticals by 37.3% in the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 5,600 shares in the last quarter. Virtu Financial LLC purchased a new position in Kalvista Pharmaceuticals in the 3rd quarter worth approximately $216,000. Dimensional Fund Advisors LP purchased a new position in Kalvista Pharmaceuticals in the 3rd quarter worth approximately $274,000. Finally, Spark Investment Management LLC purchased a new position in Kalvista Pharmaceuticals in the 2nd quarter worth approximately $108,000. 56.75% of the stock is currently owned by institutional investors.

NASDAQ:KALV traded down $0.08 on Friday, hitting $18.85. The stock had a trading volume of 6,951 shares, compared to its average volume of 69,752. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $23.97. The stock has a market capitalization of $323.82 million, a price-to-earnings ratio of -12.22 and a beta of 2.87.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.